← Companies|Ruijin Hospital
Ru

Ruijin Hospital

NPShanghai CNFounded 19074,000 employees
Private CapacadPrivateHematologyOncology
Platform: Teaching Hosp
Market Cap
N/A
All Drugs
8
Clinical Trials
8
Failed / Terminated
3
FDA Approved
2
Drug Pipeline (8 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
RUI-IIT-209RUI-IIT-209Preclinical1mRNAGIP-RPLK4iThymoma
RUI-IIT-588RUI-IIT-588NDA/BLA1PeptideCGRPCl18.2PNH
RUI-IIT-543RUI-IIT-543Phase 2/31Bispecific AbB7-H3MDM2iCervical Ca
RUI-IIT-701RUI-IIT-701Phase 11RadioligandCDK2C5iSMA
RUI-IIT-267RUI-IIT-267Approved1Gene EditingPD-L1BiTEHemophilia A
RUI-IIT-202RUI-IIT-202Phase 11siRNAWEE1FXIaiOCD
RUI-IIT-706RUI-IIT-706NDA/BLA1Gene EditingCGRPKIF18AiALS
RUI-IIT-540RUI-IIT-540Approved1Fusion ProteinTIM-3JAK1/2iNSCLC
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (8)
2025-03-06
RUI-IIT-209 Interim
Thymoma
Past
2026-10-07
RUI-IIT-588 Ph3 Readout
PNH
Ph3 Readout
2027-09-27
RUI-IIT-202 Interim
OCD
Interim
2027-12-07
RUI-IIT-543 Ph3 Readout
Cervical Ca
Ph3 Readout
2030-03-06
RUI-IIT-540 Ph3 Readout
NSCLC
Ph3 Readout
2030-03-25
RUI-IIT-706 Ph3 Readout
ALS
Ph3 Readout
2030-09-18
RUI-IIT-701 Interim
SMA
Interim
2031-01-23
RUI-IIT-267 Ph3 Readout
Hemophilia A
Ph3 Readout